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Mycobacterium tuberculosis
Rv3160c is a TetR‑like
transcriptional repressor
that regulates expression
of the putative oxygenase Rv3161c
Hasan Tükenmez1,2,3,4*, Souvik Sarkar1,3, Saber Anoosheh1,3, Anastasiia Kruchanova2,3,
Isabel Edström2,3, Gregory A. Harrison5, Christina L. Stallings5, Fredrik Almqvist1,3 &
Christer Larsson2,3,6*
Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is a major health threat listed among the
top 10 causes of death worldwide. Treatment of multidrug-resistant Mtb requires use of additional
second-line drugs that prolong the treatment process and result in higher death rates. Our team
previously identified a 2-pyridone molecule (C10) that blocks tolerance to the first-line drug isoniazid
at C10 concentrations that do not inhibit bacterial growth. Here, we discovered that the genes rv3160c
and rv3161c are highly induced by C10, which led us to investigate them as potential targets. We show
that Rv3160c acts as a TetR-like transcriptional repressor binding to a palindromic sequence located
in the rv3161c promoter. We also demonstrate that C10 interacts with Rv3160c, inhibiting its binding
to DNA. We deleted the rv3161c gene, coding for a putative oxygenase, to investigate its role in drug
and stress sensitivity as well as C10 activity. This Δrv3161c strain was more tolerant to isoniazid and
lysozyme than wild type Mtb. However, this tolerance could still be blocked by C10, suggesting that
C10 functions independently of Rv3161c to influence isoniazid and lysozyme sensitivity.
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is still a major infectious disease worldwide1.
In 2018, an estimated 10 million people fell ill with TB and 1.5 million died g lobally1. The fight against TB is
exacerbated by the emergence of multidrug-resistant strains (MDR-TB) resistant to at least two of the first-line
drugs to treat TB, isoniazid (INH) and r ifampicin1. These infections require additional second-line drugs and
longer duration of treatment where the treatment success rate drops substantially1. Over the last 50 years, only
three new TB drugs have been developed and approved for use against TB: bedaquiline, delamanid and most
recently, pretomanid. However, there are already several cases reported with TB resistant to both bedaquiline
and delamanid2–5. Therefore, there is still a desperate need to develop new strategies to target drug-resistant Mtb.
Previously, our team described a thiazolo ring-fused 2-pyridone (C10) with the ability to increase sensitivity
to oxidative stress, acid stress and the first-line antibiotic INH6. C10 was found to potentiate the bactericidal
activity of INH and prevent the occurrence of INH-resistant m
 utants6. Moreover, INH-resistant katG mutants
were re-sensitized to INH in the presence of C10, demonstrating that INH resistance can be circumvented6. We
also showed that C10 inhibited respiration in Mtb, and previous reports have shown that both inhibition and
stimulation of Mtb respiration can potentiate bactericidal activity of INH7,8. However, the link between C10
effects on respiration and C10 effects on INH sensitivity were not elucidated. The C10 target(s) in Mtb as well as
molecular mechanism of the INH potentiation is unknown.
Here, we discovered the rv3160c-rv3161c operon to be induced by C10 in Mtb. We found that C10 inhibits
DNA-binding activity of Rv3160c, a putative TetR-like transcription factor, and results in increased expression
of Rv3161c, a protein of unknown function related to oxygenases found in other bacteria. When knocked out,
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Figure 1.  Expression of the rv3160c-rv3161c operon is significantly induced by C10-IMD. Mtb Erdman WT
was cultivated in Sauton’s medium at 37 °C until its OD600 reached 0.3. The cells were then exposed to 0.1%
DMSO, 0.1 µg/ml INH and 25 µM C10-IMD separately or in combination for 48 h at 37 °C. Differences in
expression of the rv3160c-rv3161c operon were determined by qRT-PCR analysis performed by targeting
rv3161c coding region. Expression of the sigA gene was determined by qRT-PCR analysis and used as
housekeeping control. Relative fold-change in rv3160c-rv3161c operon expression was calculated for each
biological replicate by the Livak (2−ΔΔCt) method. Bar graphs were plotted based on average and standard
deviation obtained from three independent biological replicates and statistical analysis comparing to the DMSO
control was determined by one-tail t-test that was performed using GraphPad Prism version 8.4.3 for Windows,
GraphPad Software, San Diego, California USA, www.graphpad.com (**p < 0.01).

Δrv3161c mutants became more tolerant to both INH and lysozyme, indicating that the Rv3161c plays an active
role in both INH potentiation and maintenance of cell wall integrity. However, the Δrv3161c mutants can still
be sensitized to both INH and lysozyme by C10, excluding the potential involvement of rv3160c-rv3161c in the
C10 effect.

Results

Expression of the rv3160c‑rv3161c operon is upregulated in response to C10.

In our previous
study, the small molecule C10 was discovered to reduce tolerance to oxidative stress, acid stress and to the first
line antibiotic INH in Mtb6. Furthermore, C10 could restore INH sensitivity in otherwise INH-resistant katG
mutants6. C10 also perturbed respiratory homeostasis, but its mechanism of action is u
 nclear6.
In order to identify the target(s) of C10 and discover the mechanism behind its INH potentiation, we revisited our previous RNA-seq data and looked closer at the top genes induced by C10. The rv3160c and rv3161c
genes, positioned within a proposed two-gene o
 peron9,10, were among the top 5 genes upregulated by C10 under
hypoxic growth conditions (13-fold and 12-fold, respectively)6. These genes particularly caught our attention,
as they have been shown to be induced by triclosan, an antibacterial that inhibits InhA, resulting in deficient
mycolic acid synthesis in Mtb, similar to I NH11,12.
According to the RNA-seq results, upregulation of the rv3160c-rv3161c operon by C10 was observed under
hypoxic growth conditions but not under aerated conditions. To investigate this further, we performed quantitative real-time PCR (qRT-PCR) analysis of the rv3160c-rv3161c operon in response to C10 molecule under aerobic
conditions. To improve solubility of C10, we used a C10-imidazole salt (C10-IMD) instead of C10 during this
study (Fig. S1)6. qRT-PCR data showed that expression of the rv3160c-rv3161c operon increases 102 ± 32-fold
under aerated growth conditions upon exposure to 25 µM C10-IMD for 48 h (Fig. 1). Furthermore, expression
of this operon was induced even further, 1035 ± 571-fold upon exposure to a combination of 25 µM C10-IMD
and 0.1 µg/ml INH for 48 h (Fig. 1). There were no significant changes in expression of the operon upon exposure
to either 0.1 µg/ml INH or 25 µM IMD alone for 48 h (Fig. 1). These findings suggest that INH and C10-IMD
have a synergistic role in the induction of the rv3160c-rv3161c operon. Based on this, we decided to investigate
the rv3160c-rv3161c operon further.

Rv3160c is a TetR‑like transcription repressor of the rv3160c‑rv3161c operon. The rv3160c gene
encodes a putative TetR family transcriptional regulator (TFTR) and is uniquely found in mycobacteria causing
TB13. Mycobacterial genomes are highly enriched with several TFTRs, of which the majority act as repressors of
gene expression13. Even though Rv3160c has been suggested to be a TFTR based on sequence domain similarities to other TFTRs, its function and possible target(s) have not been described. The majority of the TetR-like
transcriptional repressors are known to regulate their neighboring genes and often to be co-transcribed with
their regulatory targets13. Several previous studies have suggested that the rv3160c and the rv3161c genes are
located within the same operon based on their correlated gene expression in response to various environmental
factors11,14–19. However, a genome wide study suggested the rv3160c gene to have its own independent transcripScientific Reports |
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Figure 2.  Rv3160c acts as transcriptional repressor of the rv3160c-rv3161c operon. (A) Schematic
representation of the rv3160c-rv3161c operon and the relative positions of the targets for CRISPRi and qRTPCR. (B,C) qRT-PCR analysis of rv3160c and rv3161c mRNA expression in Mtb Erdman WT strain harboring
either vector control (pJR965) or the rv3160c-CRISPRi (pSA253) construct in absence (−) or presence (+) of
100 ng/ml aTc. sigA mRNA expression was used as control and relative fold change in rv3160c and rv3161c
mRNA expression were calculated for each biological replicate by the Livak ( 2−ΔΔCt) method. Average value
of 3 technical replicates was used for each biological replicate. Bar graphs were plotted based on average and
standard deviation obtained from three independent biological replicates and statistical analysis was determined
by one-tail t-test that was performed using GraphPad Prism version 8.4.3 for Windows, GraphPad Software, San
Diego, California USA, www.graphpad.com (*p < 0.05, **p < 0.01).
tional start site (TSS) starting at 406 bp upstream of the rv3160c open reading frame (ORF), overlapping with
the rv3161c ORF20. To determine which promoter region was responsible for the transcription of rv3160c in
our conditions, we measured the expression levels of the rv3160c gene while targeting the region between the
rv3160c-rv3161c operon TSS and the recently proposed independent TSS of the rv3160c gene with a CRISPRi
construct (Fig. S2). We found that the expression of the rv3160c gene was significantly reduced suggesting that
rv3160c is mainly co-transcribed with the rv3161c gene (Fig. S2). However, the existence of additional TSSs,
perhaps of importance in response to other conditions, cannot be excluded based on this data.
We designed an experiment to test whether expression of the neighboring rv3161c gene was regulated by
Rv3160c (Fig. 2A). We reduced expression of rv3160c gene (~ threefold) by rv3160c-CRISPRi (Fig. 2B), which
resulted in a 33 ± 3-fold increased expression of the rv3161c gene (Fig. 2C). This data shows that decreasing
rv3160c expression results in an increase in rv3161c expression, although it does not show whether this occurs
through direct regulation or not.
TFTRs typically bind to palindromic motifs as dimers, thus we searched for such motifs in the upstream
sequence of the rv3160c-rv3161c operon. We identified a stretch of 50 bp containing 12-bp and 8-bp inverted
repeats starting at the − 29 bp upstream of the operon (Fig. 3A). We confirmed that Rv3160c binds to a 142 bp
DNA fragment containing these palindromic motifs, resulting in a DNA shift using the electrophoretic mobility shift assay (EMSA) (Fig. S3). We then digested the 142 bp DNA fragment with different restriction enzymes
to narrow down the region that is targeted by Rv3160c (Fig. S3). We found that that presence of both inverted
repeats as well as the − 10 region were necessary for an efficient interaction, thus we decided to use 86 bp DNA
fragment containing both these palindromic motifs for the remaining EMSAs (Fig. 3B). The binding of Rv3160c
to these palindromes would block access of the RNAP to the − 10 sigma factor binding site and repress transcription of the rv3161c. To test if the palindromic motifs were important for Rv3160c binding, we performed EMSAs
with modified DNA fragments. We used a higher concentration of Rv3160c (100 pmol) in these assays compared
to those presented in Fig. 3 (10 pmol) to ensure the protein was in excess to detect lower affinity binding events.
In these experiments, we observed that our DNA dye bound to purified Rv3160c (Fig. S4), obscuring the shifted
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Figure 3.  Binding of Rv3160c to the rv3160c-rv3161c operon is blocked by C10-IMD. (A) Schematic depicting
model of the Rv3160c dimer binding to the palindromic sequence present in the rv3161c upstream fragment.
(B) EMSA assay using an 86 bp rv3161c upstream fragment (1 pmol; lanes 1–3) and a 204 bp cfp10 upstream
fragment as negative control fragment (1 pmol; lanes 4–5). Lane 1 and 5: no protein added. Lanes 2, 3 and 5:
binding reaction with 10 pmol Rv3160c. Lane 3: 50 nmol C10-IMD. DNA Ladder: Thermo Scientific GeneRuler
1 kb Plus (SM1331).
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DNA band. Nevertheless, this interaction would not interfere with the migration of the band in the acrylamide
gels as staining took place after the gel runs were completed. We evaluated Rv3160c binding by quantifying the
amount of unbound DNA in the presence of Rv3160c as a percentage of the unbound DNA in the absence of
Rv3160c for each DNA construct. To test if the inner palindrome is important for Rv3160c binding, we shuffled the 8 bp inverted repeats in the inner palindrome, without eliminating the palindrome structure or base
composition (Fig. S5A). Rv3160c showed decreased binding to the fragment harboring a shuffled inner palindrome, leaving 83% of the DNA unbound, as compared to the unmodified fragment, where only 8% of the DNA
remains unbound by Rv3160c (Fig. S5B). We then incubated Rv3160c with DNA fragments harboring a shuffled
outer palindrome or harboring both shuffled inner and outer palindromes and found that nearly all of the DNA
remained unbound in the presence of Rv3160c (Fig. S5). Furthermore, by modifying the two non-matching
nucleotides located between the inner and outer palindromes to create a single 21 bp inverted repeat, we found
that Rv3160c was still able to bind most of the DNA fragment, leaving 37% of the DNA unbound (Fig. S5A).
These findings demonstrate that the ability of Rv3160c to bind the sequence upstream of rv3161c is dependent
on the sequence of both inverted repeats.

C10‑IMD inhibits the interaction between Rv3160c and the rv3161c upstream target
sequence. As mentioned above, expression of the rv3160c-rv3161c operon is induced by C10-IMD. Thus,

we hypothesized that C10-IMD might interfere with Rv3160c function. Indeed, we found that Rv3160c was
no longer capable of interacting with the sequence upstream of rv3161c in the presence of C10-IMD in the
EMSA (Fig. 3B). To investigate whether C10-IMD interacted directly with Rv3160c, we analyzed the effect of
C10-IMD on Rv3160c tryptophan fluorescence emission. There are 3 tryptophan residues available in Rv3160c
and the binding interaction between C10-IMD and Rv3160c was studied using tryptophan fluorescence. The
presumption is that if C10-IMD binds Rv3160c and some of the tryptophan residues are in close proximity to
the C10-IMD binding site, compound binding might affect the intrinsic fluorescence of Rv3160c. Rv3160c was
titrated with increasing concentrations of C10-IMD and relative fluorescence intensity was found to decrease in
a concentration-dependent manner (Fig. 4A). The fluorescence quenching was further analyzed by Stern–Volmer equation (Eq. 1, see “Methods” section) to determine the Stern–Volmer quenching constant (Ksv) (Fig. 4B),
which signifies the equilibrium binding constant for complex formation in the light-induced electronic excited
state resulting in the quenching of intrinsic fluorescence of tryptophan. In this study, the Stern–Volmer plot
analyzes the type of fluorescence quenching of tryptophan residues in Rv3160c by plotting relative emission
intensity against C10-IMD concentration. In the case of Rv3160c, a tryptophan might be buried in the protein,
whose fluorescence quenching depends on the microenvironment, solvent accessibility, and binding of C10IMD. Overall, the tryptophan fluorescence quenching is a combined contribution of the microenvironment of
all tryptophan residues in the presence of C10-IMD. If tryptophan residues are in close proximity of C10-IMD
binding site, C10-IMD binding leads to fluorescence quenching of tryptophan while the fluorescence of other
tryptophan residues that are not involved in C10-IMD binding would not be quenched. The Stern–Volmer plot,
therefore, helps to understand the binding process leading to quenching phenomena21. To calculate the binding
dissociation constant (KD) and the number of binding site (n), the logarithmic Eq. (2) (see “Methods” section)
was used. The log(Kb) (Kb denotes binding association constant) value had been determined from the intercept
of the plot, shown in Fig. 4C. The binding dissociation constant ( KD) was found to be 44.51 ± 0.85 µM using
Eq. (3). The number of binding sites for the C10-IMD in Rv3160c was found to be 0.94 ± 0.09 suggesting one
binding site of C10-IMD in Rv3160c.
TFTRs usually consist of two domains: one signal-receiving and the other one DNA-binding. Interactions
of TFTRs with their target DNAs often lead to structural changes, especially in the DNA-binding domain22–25.
Similarly, specific molecules can bind to the regulatory domain of TFTRs, resulting in conformational changes
that make TFTRs incapable of binding their DNA t argets26,27. According to our EMSA experiments, Rv3160c
cannot bind to its DNA target upon addition of C10-IMD. Thus, we investigated whether interaction with C10IMD results in conformational changes in Rv3160c using circular dichroism (CD) spectroscopy. We discovered
that the ellipticity of Rv3160c was reduced upon addition of its DNA target, indicating changes in the secondary
structure (Fig. 4D). In contrast, no change in the ellipticity of Rv3160c was observed in the presence of C10-IMD
(Fig. 4E), indicating that C10-IMD did not alter the secondary structure of Rv3160c in the absence of DNA.
There is a slight change in the ellipticity in the presence of C10-IMD approximately at 208 nm in Fig. 4E does
not have much impact on overall secondary structure of Rv3160c.

Deletion of rv3161c results in increased sensitivity to INH and lysozyme. C10-IMD directly

binds Rv3160c, a TetR-like transcriptional repressor, which could be leading to the increased expression of the
rv3160c-rv3161c operon in the presence of C10-IMD. We hypothesized that INH potentiation by C10-IMD
might be regulated through the cellular concentration of Rv3161c, a putative oxygenase. To test this, we used
recombineering to generate a rv3161c knock-out strain and tested its sensitivity to INH. Both wild type and
Δrv3161c strains were incubated for 2 weeks at 37 °C with varying concentrations of INH in U-bottomed 96-well
plates. After 2-weeks incubation, we scored the pellet formations in each well as a semi-quantitative indication
of bacterial growth and spotted them on 7H10 plates followed by additional 3-weeks of incubation at 37 °C
to assess the presence of viable bacteria. We discovered that the Δrv3161c strain was more resistant to INH in
comparison to wild type, as it could survive up to double the INH concentration (0.016 µg/ml) (Fig. 5). We also
observed that addition of 5 µM C10-IMD potentiated INH sensitivity in both wild type and Δrv3161c strains,
demonstrating that the effect of C10-IMD on INH potentiation occurs independently of Rv3161c (Fig. 5).
Previous studies show that expression of the rv3160c-rv3161c operon is upregulated in the lipid-rich
environments18 and upon treatment with cell wall synthesis inhibitors11,17,19, raising the question of whether
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Figure 4.  C10-IMD binds to a single site in Rv3160c and the interaction does not cause changes in the
secondary structure of the protein. (A) Fluorescence quenching spectra of Rv3160c. The 10 µM Rv3160c in PBS
solution is excited and quenching of fluorescence is recorded in the presence of varying concentrations of C10IMD (1–100 μM). (B) Stern–Volmer plot of decrease in mean fluorescence intensity of Rv3160c in the presence
of varying concentrations of C10-IMD derived from three independent experiments. The dynamic quenching
rate constant Ksv is evaluated from the slope of the line. (C) Logarithmic plot of mean relative fluorescence
quenching of Rv3160c derived from three independent experiments against logarithmic concentrations of
C10-IMD. KD is calculated from the intersection of the line with the y axis and the number of binding sites (n)
from the slope of the line. (D) CD spectra of Rv3160c in the presence of 1 µM or 10 µM 86 bp rv3161c upstream
fragment (DNA) (Fig. 2C). (E) CD spectra of Rv3160c in the presence of 10 µM or 100 µM C10-IMD. Error bars
in (B) and (C) indicate standard deviation.
these genes play a role in cell wall integrity. We set up a similar growth and survival assay to test the cell wall
integrity of both wild type and Δrv3161c strains by incubating them in the presence of varying concentrations
of lysozyme, an antimicrobial enzyme that cleaves the peptidoglycan component of the bacterial cell wall. The
Δrv3161c strain survived exposure up to double the lysozyme concentration (62.5 µg/ml) compared to the wild
type strain (Fig. 5). In addition, we found that both the wild type and Δrv3161c strains were more sensitive to
lysozyme in the presence of 5 µM C10-IMD (Fig. 5).

Discussion

Expression of the rv3160c-rv3161c operon has been reported to be induced by various anti-microbial agents
such as t riclosan11,19, thioridazine16,17,19, SRI#96715, SRI#919015 and chlorpromazine19. Rv3161c encodes a putative oxygenase that shares high amino acid sequence identity (32–62%) with other Rieske oxygenases found in
several organisms. Rieske oxygenases are known to be involved in the degradation of arenes, therefore it has
been suggested that Rv3161c might hydroxylate the benzene ring structures found in these anti-microbial agents
resulting in d
 etoxification11,15,17. However, neither deletion nor overexpression of the rv3161c gene influenced the
minimal inhibitory concentration (MIC) of triclosan or other anti-microbial a gents28. Therefore, upregulation
of rv3161c expression was suggested to be a failed attempt of the bacteria to counteract these drugs28. In another
study, mutations in the rv3161c gene were found to cause resistance against the 2,4-diaminoquinazoline (DAQ)
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Figure 5.  Deletion of the rv3161c gene results in higher resistance to isoniazid and lysozyme. (A)
Representative images showing effect of INH and lysozyme on bacterial growth scored by pellet formation. Mtb
Erdman WT and ∆rv3161c strains were incubated 2 weeks in Sauton’s medium with 0.02% DMSO or 5 µM
C10-IMD in addition to various concentration of INH (left; 0.002–0.064 µg/ml) or lysozyme (right; 3.9–125 µg/
ml). (B) Representative images showing effect of INH and lysozyme treatment on bacterial survival scored by
spotting bacteria exposed to INH (left; 0.002–0.064 µg/ml) or lysozyme (right; 3.9–125 µg/ml) in the presence of
0.02% DMSO or 5 µM C10-IMD on antibiotic-free 7H10 plates.

anti-tubercular agent and Rv3161c was proposed to convert pro-drug DAQ into its active form29. Despite all of
these previous studies, the mechanism of action of the Rv3161c in response to antimicrobial agents is still unclear.
We discovered that rv3161c is highly expressed in response to the C10-IMD compound that previously
has been shown to potentiate INH s ensitivity6. Induced rv3161c expression was also observed as a response to
2-aminoimidazoles (2-AI), a class of molecules that potentiate sensitivity to β-lactam antibiotics by increasing cell p
 ermeability14. Several studies have suggested that Rv3161c is involved in lipid metabolism and cell
wall biogenesis11,17–19. In this study, we found that Δrv3161c mutants become more resistant to INH as well
as lysozyme, an enzyme degrading the peptidoglycan layer of the cell wall (Fig. 5). We hypothesize that elevated Rv3161c may disturb the cell wall integrity and increase cell permeability, resulting in increased INH and
lysozyme sensitivity. The Δrv3161c mutants can still be sensitized against both INH and lysozyme by C10-IMD,
demonstrating that C10-IMD functions independent of Rv3161c to elicit these effects (Fig. 5). We tried to generate a Δrv3160c mutant to test whether elevated Rv3161c in the absence of C10-IMD could increase sensitivity
against INH and lysozyme, however we failed to generate such a mutant in several attempts.
In this study, we clarified the function of Rv3160c as a TetR-like transcriptional repressor that regulates
rv3161c expression. Despite the fact that several publications have suggested the rv3160c-rv3161c operon to
be involved in key processes such as drug detoxification, lipid metabolism and cell wall biogenesis11,14–19,29, the
function of the Rv3161c remains unknown. Further investigation aiming to elucidate the function of Rv3161c
will lead to important insights into Mtb biology.

Methods

Bacterial strains and growth conditions. WT E. coli DH5α was grown in Luria Broth (Difco) as shaking cultures at 37 °C and kanamycin at 50 µg/ml was used for selection when required.
WT Mtb Erdman and the rv3161c knockout with Mtb Erdman background were grown in either Middlebrook 7H9 medium (BD Difco) supplemented with 0.05–0.1% Tween80 and 10% ADS (0.5% albumin, 0.2%
dextrose and 0.085% saline) or Sauton’s medium [0.0005% (w/v) K
 H2PO4, 0.0005% (w/v) M
 gSO4, 0.004% (w/v)
l-asparagine, 0.06% glycerol, 0.00005% (w/v) ferric ammonium citrate, 0.002% (w/v) citric acid, 0.0001% Z
 nSO4,
pH 7] supplemented with 0.1% Tween80 as liquid shaking cultures at 37 °C. These strains were also grown on
Middlebrook 7H10 solid medium (Remel) supplemented with 0.05% Tween80, 0.2–0.5% Glycerol and 10% ADS
at 37 °C. Kanamycin at 20 µg/ml and anhydrotetracycline (aTc) at 100 ng/ml were used when required. All the
strains used in this work are listed in Table S1.
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Construction of rv3160c‑CRISPRi and rv3161c‑CRISPRi strains. To investigate regulation of the

rv3160c-rv3161c operon, we silenced expression of the rv3160c and the rv3161c genes individually by using the
dCas9Sth1 CRISPRi s ystem30. This system utilizes a catalytically inactivated CRISPR1 cas9 allele and provides an
RNA-guided platform for sequence-specific control of gene expression. The single guide RNAs (sgRNAs) for
each gene were determined and ranked by PAM score. Forward and reverse oligonucleotides (Table S2) corresponding to the top-ranked sgRNA sequence for each gene were annealed together to form double stranded
DNA fragments and subsequently cloned into the BsmBI site of pLJR965 as described b
 efore30. The resulting
plasmids, named pSA253 (targeting rv3160c) and pSA256 (targeting rv3161c), were electroporated into Mtb
Erdman to obtain TB3 and TB4 respectively.

RNA isolation and cDNA synthesis. Mtb Erdman strains harboring pLRT965 (empty vector), pSA253
(targeting rv3160c) or pSA256 (targeting rv3161c) were grown in 7H9 medium supplemented with 0.05%
Tween80, 10% ADS and 20 µg/ml kanamycin until their optical density (OD600) reaches to 0.3 in the presence of
aTc (100 ng/ml) to induce expression of gene-specific sgRNA. Same strains were also cultivated similarly but in
the absence of aTc as non-induced controls. Equivalents of 6 OD600-unit cells were harvested by centrifugation
and resuspended in 1 ml TRI Reagent (Invitrogen). Cell suspensions were transferred into screw-cap homogenizing tubes containing 0.4 ml of 0.1 mm Zirconia/Silica beads (BioSpec) and lysed in a bead beater 8 times for
30 s with a 1-min rest on ice between each cycle. After a centrifugation at 13,000 g for 45 s, supernatants were
transferred into new tubes and mixed with 300 µl chloroform followed by incubation at room temperature for
2 min. The samples were centrifuged at 13,000 g for 5 min and aqueous phase were transferred into new tubes.
An equal volume of absolute ethanol was mixed with each sample and subsequently transferred into RNeasy columns (Qiagen) followed by purification according to the manufacturer’s instruction. Isolated RNA samples were
then DNase-treated with TURBO DNA-free kit (Invitrogen) to eliminate any genomic DNA contamination.
cDNA was prepared using qScript cDNA Synthesis kit (Quantabio) according to the manufacturer’s instruction.
Quantitative real‑time PCR. Expression levels of rv3160c and rv3161c genes were determined by qRTPCR with cDNA equivalent to 50 ng RNA using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific) and the oligonucleotides listed in Table S3. RNA samples that were not reverse transcribed were used to
confirm that there were no DNA contamination, and the integrity of the amplicons were confirmed by melting
curves for each sample. All qRT-PCR experiments were performed with three technical replicates derived from
three biological replicates. Signals were normalized to the housekeeping sigA mRNA and quantified by the Livak
(2−ΔΔCt) method31. The Ct values of induced samples were compared to the corresponding Ct values of uninduced samples. Statistical analysis was performed using the one-tailed t-test and the results were plotted as bar
graphs based on average and standard deviation obtained from three biological replicates by GraphPad Prism
version 8.4.3 for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com.
Electrophoretic mobility shift assay.

EMSA was performed with 142 bp rv3161c upstream fragment
(undigested or digested with BglI, HincII or TaqI), 86 bp rv3161c upstream fragment (wild type or altered) or
204 bp cfp10 upstream fragment. The 142 bp rv3161c upstream sequence was directly amplified from chromosomal DNA with BS3161F and BS3161R oligonucleotides. Complementary oligonucleotides bearing the 86 bp
rv3161c upstream sequence (wild type or altered) were annealed and amplified with UniPal_F and UniPal_R
oligonucleotides (Table S4). cfp10 upstream sequence was also directly amplified from chromosomal DNA with
EMSA_CFP10-F and EMSA_CFP10-R oligonucleotides (Table S4). The binding reactions were prepared in
10 mM Tris–HCl (pH 8.0), 150 mM KCl, 0.5 mM EDTA (pH 8.0), 0.1% Triton-X 100, 12.5% glycerol, 0.2 mM
DTT, 0.1 mg/ml BSA and 10 ng/ul Poly-dIdC in the presence of 1 or 4 pmol DNA targets, 10 or 56 pmol Rv3160c
(produced by the Protein Expertise Platform at Umeå University in 1× PBS) and/or 50 nmol C10-IMD and
incubated for 30 min at 37 °C. Reaction mixes were then loaded onto 6% polyacrylamide gels and run at 80 V
in 0.5% TBE buffer for 75 min. The gels were then stained in 3× GelRed (Biotium) buffer for 15 min followed by
washing with MQ water for 15 min twice. The DNA was visualized with UV-transilluminator and signals were
analyzed by Image J Software version 1.52a32.

Fluorescence spectroscopy.

The interaction between C10-IMD and Rv3160c was analyzed by concentration-dependent response of C10-IMD on Rv3160c tryptophan fluorescence emission measured in Hitachi
F-4500 fluorescence spectrophotometer. Rv3160c emission spectra were acquired using 10 μM of protein dissolved in 1× PBS (pH 6.8) with or without adding C10-IMD and was incubated for 1 min at 37 °C in a quartz
cuvette. The resulting solution was excited at 290 nm for tryptophan residue and the intrinsic fluorescence emission was scanned from 300 to 460 nm. The data from each read was then combined and plotted using the Spectragryph Software version 1.2.1333. The fluorescence quenching data have been corrected for inner filter effects.
Fluorescence quenching was determined by analyzing the data by the classical Stern–Volmer equation:

F0 /F = 1 + kq τ0 [Q] = 1 + Ksv [Q]

(1)

where Fo and F are the fluorescence intensities in the absence and presence of the quencher, respectively. Kq is the
bimolecular quenching rate constant and Ksv is the dynamic quenching constant. Average lifetime of the protein
in absence of the quencher is expressed in terms of τo whereas [Q] is the concentration of the free quencher.
When small molecules interact with several comparable sites in a protein, the equilibrium between liberated and
bound molecules is expressed by the equation:
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log((F0 − F)/F) = logKb + n log[Q]

(2)

KD = 1/Kb

(3)

where Kb represents binding constant for quencher-protein interaction, n is the number of binding sites per
molecule of Rv3160c, K
 D denotes binding dissociation constant.

Circular dichroism (CD) spectroscopy. CD spectroscopy was performed with Rv3160c as described
earlier34. The native secondary structure of Rv3160c was compared using far-UV range CD spectra in presence
of various concentrations of C10-IMD (10 µM and 100 µM) and 86 bp rv3161c upstream DNA bait (1 µM and
10 µM). The spectra were recorded using Jasco CD spectrometer at a range of 200 to 260 nm from 10 µM of
Rv3160c in optically clear buffer under the nitrogen atmosphere at 25 °C. The buffer baseline corrected spectra
were processed with an average of 5 scans and presented as units of mean residue ellipticity.
Impact of isoniazid and lysozyme on bacterial growth and survival. The bactericidal/bacteriostatic properties of isoniazid and lysozyme were assayed at varying concentrations (0.002–0.064 µg/ml for INH
or 3.9–125 µg/ml for lysozyme) in Sauton’s medium with 0.02% DMSO or 5 µM C10-IMD for both Mtb Erdman
wild type and Δrv3161c strains as described in our previous s tudy35.
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